Table 1.
Characteristics of the included prospective cohort studies
| Study | Region | N | Age | Male/female | Schedule | Child-Pugh | CLIP (0/1/2/3/4) | Prior therapy | ECOG (0/1/2) | BCLC (A/B/C) | Liver disease | Line of therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Melanie 2018 [28] | USA | 90 | 61 | NA | Arm1: S(400 mg, Q2D, oral) Arm2: B (10 mg/kg, Q2w) + E (150 mg/d, oral) |
S:A88%;B12% B + E:A83%;B17% |
S:4/10/17/9/3 B + E:7/10/16/8/6 |
NA | S:17/25/1 B + E: 15/32/0 |
S: A9%B26%C65% B + E: A2%B30%C68% |
NA | First |
| Kaseb 2016 [24] | Egypt | 44 | 63 | 33/11 | B(10 mg/kg, Q2w) + E(150 mg/d, oral) | A98%, B2% | 5/17/12/7/0 | Sorafenib | 15/29/0 | A5%B2%C93% | HBV8; HCV13 Alcoholism10 Cirrhosis19 |
Second |
| Govindarajan 2013 [21] | USA | 21 | 60 | 13/8 | B(15 mg/kg, Q3w) + E(150 mg/d, oral) | A85.7%, B14.3% | NA | NA | NA | A0%B23.8% C76.2% | HBV1; HCV6 HCV + HBV2 |
First |
| Hsu 2013 [22] | Taiwan | 51 | 58 | 44/7 | B(5 mg/kg, Q2w) + E (150 mg/d, oral) | A98%, B2% | 15/8/11/12/5 | NA | 30/20/1 | A0% B11.7% C88.3% |
HBV42;HCV4 HBV + HCV3 | First |
| Philip 2012 [25] | USA | 27 | 60 | 20/7 | B(10 mg/kg, Q2w) + E(150 mg/d, oral) | A74%, B26% | NA | Sorafenib | 16/11/0 | NA | HBV1; HCV8 Alcoholism2; Cirrhosis6 |
Second |
| Yau 2012 [27] | China | 10 | 47 | 7/3 | B(10 mg/kg, Q2w) + E(150 mg/d, oral) | A100% | NA | Sorafenib | 0/10/0 | A0% B10%, C90% |
HBV10 Cirrhosis10 |
Second |
| Kaseb 2012 [23] | USA | 59 | 64 | 13/46 | B(10 mg/kg, Q2w) + E(150 mg/d, oral) | A86% B14% |
3/14/13/22/7 | Sorafenib(7/59) | NA | A3.4%B20.3% C76.3% | HBV10; HCV17 Alcoholism 27 |
NA |
| Melanie 2009 [26] | USA | 40 | 64 | 31/9 | B(10 mg/kg, Q2w) + E(150 mg/d, oral) | A87.5%, B12.5% |
2/11/6/16/5 | Sorafenib(8/40) | 19/20/1 | A5%B30% C65% | HBV6; HCV10 Alcoholism17 Cirrhosis27 |
NA |
Note: B bevacizumab, E erlotinib, S sorafenib, NA not available